Comparative Pharmacology
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus RESPORAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFIZOX IN PLASTIC CONTAINER versus RESPORAL.
CEFIZOX IN PLASTIC CONTAINER vs RESPORAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to penicillin-binding proteins (PBPs) in bacterial cell wall, inhibiting peptidoglycan cross-linking, leading to cell lysis and death.
RESPORAL contains theophylline, a methylxanthine that inhibits phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cAMP and cGMP levels. It also antagonizes adenosine receptors, resulting in bronchodilation and anti-inflammatory effects.
1-2 g IV/IM every 8-12 hours; severe infections: up to 2 g every 6-8 hours; maximum 12 g/day.
2 mg orally twice daily
None Documented
None Documented
1.5-2 hours; prolonged to 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal half-life is 12 hours (range 10-14 h), supporting twice-daily dosing in most patients.
Primarily renal (80-90% unchanged), with biliary/fecal elimination being minor (<10%)
Renal excretion accounts for 70% of elimination (30% unchanged), biliary/fecal 20%, and 10% metabolized.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic